Spyre Therapeutics, Inc. (SYRE) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Spyre Therapeutics, Inc. (SYRE:NASDAQ), powered by AI.

Current Price
$83.41
P/E Ratio
-34.4
Market Cap
5.3B
Sector
Healthcare
What is the Spyre Therapeutics, Inc. stock price forecast?

Spyre Therapeutics, Inc. is currently trading at $83.41. View real-time AI analysis on Alpha Lenz.

What is Spyre Therapeutics, Inc. insider trading activity?

View the latest insider trading data for Spyre Therapeutics, Inc. on Alpha Lenz.

What is Spyre Therapeutics, Inc.'s P/E ratio?

Spyre Therapeutics, Inc.'s P/E ratio is -34.4.

Spyre Therapeutics, Inc.

NASDAQ · SYRE
$83.41-0.17(-0.20%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Spyre Therapeutics, Inc.'s future dividend policy...
Alpha Chat Insight

Spyre Therapeutics, Inc. trades at a P/E of -34.4 (undervalued) with modest ROE of -25.2%.

Ask for details

Company Overview

Spyre Therapeutics Inc. operates as a biopharmaceutical company focused on developing innovative therapies for autoimmune and inflammatory diseases. Its primary function is to research and bring to market novel medicines that target the underlying causes of these conditions, improving patient outcomes and quality of life. Spyre Therapeutics is actively involved in the biotechnology sector, where it leads efforts in drug discovery and development, leveraging cutting-edge technologies to identify new therapeutic pathways. The company's pipeline includes a range of biologic and small molecule drugs, each designed to address specific immune system dysregulations. In the financial market, Spyre Therapeutics plays a crucial role as a potential driver of growth within the biotech industry, attracting attention from investors interested in companies with promising research and development capabilities. The company's advancements can lead to significant healthcare impacts, offering progressive treatments in areas of significant unmet medical need.

CEODr. Cameron Turtle DPHIL, Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees65

Company Statistics

FY 2025

Profile

$5.34BMarket Cap
$0.00Revenue
0.00Shares Out
65Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-34.43P/E
7.47P/B
N/AEV/Sales
-22.90EV/EBITDA
-31.57P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-22.39%ROA
-25.17%ROE
-31.68%ROIC

Financial Health

$85.72MCash & Cash Equivalents
$-23.18MNet Debt
8.74%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Spyre Therapeutics, Inc. (ticker: SYRE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 65 employees. Market cap is $5.3B.

The current price is $83.41 with a P/E ratio of -34.43x and P/B of 7.47x.

ROE is -25.17%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Spyre Therapeutics, Inc. (SYRE) Stock Forecast 2026 $83.41 — Price, Financials & Analyst Targets | Alpha Lenz